All lobbying filings

Ferox Strategies

Ferox Strategies filed a Q3 termination report for Avidity Biosciences, Inc. on October 19, 2026, reporting $20,000 in lobbying income.

Lobbying for Avidity Biosciences, Inc. · Biotechnology company.

As filed: FEROX STRATEGIES for AVIDITY BIOSCIENCES, INC.

All filings by Ferox Strategies · Everything Avidity Biosciences, Inc. has reported

Filing · LD-2 quarterly report Q3 termination

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$20,000

What the client paid this registrant for the period.

Client based in

California

Representation ended

Jul 24, 2026

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.